SUBSCRIBE
SUBSCRIBE

Cervical cancer

Pictured: Pfizer's signage at its world headquarters in New York
FDA
Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer
Based on strong overall and progression-free survival data in its Phase III confirmatory study, Pfizer and Genmab’s antibody-drug conjugate Tivdak on Monday secured the FDA’s full approval for recurrent or metastatic cervical cancer that had progressed on or after chemotherapy.
April 30, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: A scientist looks into a microscope
Drug Development
5 Successful Phase III Oncology Trials in Q1
2024 began with several biopharma players posting positive Phase III data that could mean new market share for the companies and longer survival times and quality of life for patients.
April 5, 2024
 · 
5 min read
 · 
Nsisong Asanga
Pictured: Merck office building in Canada
Drug Development
Merck’s Keytruda Pushes Towards Earlier Stages of Cervical Cancer with Phase III Data
The PD-1 inhibitor Keytruda significantly improved overall survival in a late-stage trial when used with chemoradiotherapy to treat patients with newly diagnosed advanced cervical cancer.
March 15, 2024
 · 
2 min read
 · 
Tristan Manalac
PRESS RELEASES
Press Releases
Novotech Releases In-Depth Report on Cervical Cancer: Addressing a Global Health Challenge
November 13, 2024
 · 
4 min read
Press Releases
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
October 24, 2024
 · 
19 min read
Press Releases
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
October 24, 2024
 · 
11 min read
Press Releases
Guided Therapeutics Announces Filing of Application for NMPA Approval to Market and Sell LuViva in China
October 23, 2024
 · 
4 min read
Press Releases
Teal Health Announces FDA Submission of the Teal Wand™ and Shares Report Showing 94% of Women Prefer At-Home Cervical Cancer Screening
October 21, 2024
 · 
6 min read
Press Releases
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
October 2, 2024
 · 
7 min read
Press Releases
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions
September 23, 2024
 · 
7 min read
Press Releases
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
September 16, 2024
 · 
19 min read
Press Releases
Cervical Cancer Market Size to Reach USD 583.4 Million by 2034, Impelled by the Widespread Adoption of Immune Checkpoint Inhibitors
August 2, 2024
 · 
10 min read